Imcyse technology adresses diseases that represent a huge medical need, in terms of number of diseases and patients, clinical severity and unsatisfactory therapeutic options. There is potential for cure of severe chronic diseases, and subsequently to induce regeneration of damaged cells and organs.
The main target indications encompass auto immune and inflammatory severe diseases such as Type 1 diabetes, multiple sclerosis, rheumatoid arthritis, etc but also rare diseases such as myasthenia gravis or neuromyelitis optica.
Existing therapies can at best attenuate the disease symptoms and slow down its progress, often with frequent and severe adverse events. There is no therapeutic opportunity of cure.
In addition to auto immune diseases, Imcyse technology has demonstrated the efficacy of the concept in animal models of allergies, including allergic asthma, and in prevention of skin graft rejection.
Imcyse technology can also be used as « add-on » therapy to other drugs or biologics that become immunogenic and loose efficacy upon chronic administration, such as monoclonal antibodies, replacement enzymes or coagulation factors. Imcyse has demonstrated a blocking of the immune response against viral vectors, which are used in gene therapy or in the development of vaccines against cancer or complex and severe infectious diseases (e.g. HIV, tuberculosis).
ImCyse technology has therefore the potential to adress numerous important medical issues